Radiofrequency Ablation (RFA) for Barrett's Esophagus

RFA (Radiofrequency Ablation) treats Barrett's esophagus, particularly when dysplasia — precancerous cell change — has been found (see the Barrett's Esophagus page for the full picture on diagnosis and dysplasia grading). Using a balloon or catheter-based device passed through a standard endoscope, controlled heat energy is applied to the abnormal Barrett's lining, destroying it so that normal esophageal tissue can regrow in its place — all without surgery or external incisions.

Yes, and the evidence supporting it is genuinely strong — including one of the more rigorous types of clinical trial available. In a landmark sham-controlled trial (comparing real RFA to a fake procedure, without patients knowing which they received), complete eradication of dysplasia was achieved in about 9 out of 10 patients with low-grade dysplasia, compared to roughly 2 out of 10 in the sham group — a clear, statistically significant result. Longer follow-up from the same research found that response was durable, with about 95% of patients maintaining complete eradication of dysplasia at two years. It's worth knowing that real-world results outside of tightly controlled trials can be somewhat more variable — one high-volume European center reported lower success rates in routine practice, underscoring that outcomes do depend on operator experience and case complexity. Overall success rates across the medical literature are generally cited around 80–90%. A real but modest risk: over 1 in 10 patients whose Barrett's is successfully treated see it return at some point, which is why ongoing surveillance matters even after a successful outcome. The section further down this page, ‘The evidence in more detail,’ has the specific study data.

• Before: endoscopy with biopsy to confirm the diagnosis and grade of dysplasia, as covered on the Barrett's Esophagus page
• During: performed under sedation via standard endoscopy; the ablation device is positioned against the Barrett's tissue and delivers controlled energy in a systematic pattern
• After: some chest discomfort or difficulty swallowing for a few days is common as the treated tissue heals and sloughs off; most patients resume normal activity quickly
• Follow-up: typically more than one treatment session is needed to fully treat the affected area, followed by surveillance endoscopy to confirm eradication and monitor for any recurrence

This section is for anyone who wants the specific research behind the summary above — it's not necessary reading to understand the basics of this procedure, but it's here for transparency.

In the original landmark sham-controlled trial (127 patients with dysplastic Barrett's esophagus), complete eradication of dysplasia occurred in 90.5% of the ablation group with low-grade dysplasia, compared with 22.7% in the sham (control) group. A follow-up durability study found that after 2 years, 95% of patients had complete eradication of all dysplasia and 93% had complete eradication of intestinal metaplasia, with a low rate of disease progression through 3 years of follow-up. A broader literature review found dysplasia eradication rates ranging from roughly 62% to 100% across published studies, and intestinal metaplasia eradication from roughly 62% to 91%, with most studies reporting eradication rates above 90% for low-grade dysplasia specifically. Real-world data from a high-volume French center found more modest results in routine practice — a 59% intestinal metaplasia eradication rate and 41% treatment failure rate — along with a 14% rate of post-treatment esophageal narrowing (stricture), all of which were successfully managed with endoscopic dilation. This real-world variability is a useful, honest counterpoint to trial-level data, and underscores why operator experience matters for this procedure.

Radiofrequency ablation is used in two distinct settings here — as Barrett's esophagus treatment, where flat dysplastic mucosa is ablated so normal lining can regrow, and as EUS-guided ablation of selected pancreatic lesions. Our gastroenterologists confirm the indication histologically before either, since ablation destroys the tissue a later diagnosis would have depended on. To have a dysplasia report reviewed, book a consultation.